Researchers conducted a study that compared virologic suppression, lipid control, and safety profiles of patients with HIV infection who switch from ritonavir-boosted darunavir to doravirine (DOR) therapy vs those who continued DOR therapy.
Researchers conducted a study that included patients with HIV infection who previously achieved virologic suppression to compare the risk for virologic failure among those who switch to a single-tablet 2-drug regimen vs those who switch to a single-tablet 3-drug regimen.
Researchers conducted a study to determine whether there is an association between increased adherence to HIV pre-exposure prophylaxis with daily emtricitabine/tenofovir disoproxil fumarate and a decreased risk for incident HIV infection.
Researchers conducted a study to determine whether integrase strand transfer inhibitor-based antiretroviral therapy is associated with lipid changes in patients with HIV infection.
Researchers sought to determine the safety and efficacy of treatment with long-acting cabotegravir plus rilpivirine in patients with HIV coinfected with asymptomatic hepatitis c virus.
Investigators conducted a study that compared the rate of persistence and re-initiation of HIV pre-exposure prophylaxis among patients treated with emtricitabine/tenofovir alafenamide vs those treated with emtricitabine/tenofovir disoproxil fumarate.
